In a study involving patients with AD or MCI, doses of 20 And 40 IU improved story recall in APOE ε4 non-carriers at both doses, whereas APOE ε4 carriers experienced significantly lower test scores at the 40 IU dose [402]. Here, APOE is linked to Alzheimer disease.